… coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of
nirmatrelvir … Covid-19–related hospitalization or death from any cause through day 28, viral …

… oral alternatives [15]. In early 2021, EMA approved the first oral antiviral against COVID-19,
ie, nirmatrelvir/… future directions regarding the use of nirmatrelvir/ritonavir in clinical practice …

… , particularly as compared with nirmatrelvir–ritonavir. In addition, the … nirmatrelvir–ritonavir
for oral treatment of symptomatic participants at high risk for progression to severe Covid-19 …

… This article reviews the 2 oral COVID-19 antiviral drugs including the mechanisms of action,
antiviral activity, pharmacokinetics, drug interactions, clinical experience including trials, …

… (EUA) for the oral antiviral nirmatrelvir for the treatment of mild-to-moderate Covid-19 in
patients who had a high risk of progression to severe disease. Patients receive nirmatrelvir for 5 …

… administration of oral nirmatrelvir/ritonavir therapy may effectively decrease the risk of
COVID-19-… With an ongoing clinical trial, the role of nirmatrelvir/ritonavir in preventing disease …

… efficacy and safety of nirmatrelvir–ritonavir in COVID‐19 patients, and … Oral nirmatrelvir
and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019 (COVID‐19…

… Nirmatrelvir is an antiviral agent for COVID-19 that may address a currently unmet need for
effective, orally administered COVID-19 … of nirmatrelvir following a single 100-mg oral dose …

… We identified those who were prescribed oral nirmatrelvir within 5 days after the positive
test … COVID-19 antiviral or antibody treatment within 30 days after the positive test (nirmatrelvir …

… the ritonavir component contained in the nirmatrelvir/r combination. The rationale is that
the desired effect on the pharmacokinetics of nirmatrelvir is already achieved with the existing …